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Interleukin-13 stimulates interleukin-6 production by human keratinocytes 
Similarity with interleukin-4 
Abstract 
Interleukin-13 (IL-13) is a recently described human lymphokine which is produced by activated T-cells. Its effect on the production of IL-6 by 
normal keratinocytes and keratinocyte cell lines of human origin was studied and compared to that of IL-4. IL-13, similarly to IL-4, stimulated IL-6 
expression by these cells in a dose- and time-dependent manner. Contamination with endotaxin was excluded by the use of polymyxin B and 
heat-inactivated cytokines. Further, we showed that IL-13, like IL-4, not only stimulated IL-6 production but also was able to induce overexpression 
of this cytokine in response to an inflammatory signal such as lipopolysaccharide (LPS). In a previous tudy, we demonstrated that IL-1 3, by inhibiting 
IL-6 and other cytokines produced by monocytes, exhibited an ~anti-in~ammato~ profile’ comparable to that displayed by IL-4, In contrast, we 
show here that IL-B, by stimulating IL-4 production by keratinocytes, may favour the instaIlation of an ~~~ato~ process at a local level and, 
here again, it acted like IL-4. Therefore, according to the type of target cell, these two ‘TH2 type’ cytokines induce similar opposing effects on IL-6 
production and are likely to be important cytokines in the regulation of inflation at bath systemic and 1ocaI levels. 
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1. Introduction 
Epidermal keratinocytes which represent a major con- 
stituent of the skin, produce various cytokines such as 
transforming growth factor a, tumor necrosis factor do, 
interferon y, ~an~o~yte-ma~rophage colony-stim~at* 
ing factor, interleukin-1 (IL-l), IL-6 and IL-8 [I]_ Of 
these, IL-6 is interesting in that it is a multifunctional 
cytokine involved in immune and inflammatory reac- 
tions, which stimulates proliferation of both epidermal 
cells and lymphocytes [2A]. These properties make it a 
possible key component of the interaction between the 
epidermis and the immune system in inflammatory and 
autoimmune skin diseases such as psoriasis or sclero- 
derma. 
In these diseases, T-cell infiltrates are frequently ob- 
served and thought to play an important role in sustain- 
ing a chranic inhalator process. IL-4, a product of 
T-helper cells, has been shown to upregulate IL-6 pro- 
duction in endothelial cells [5], in skin fibroblasts [6] and 
in keratinocytes [7], whereas it downregulates IL-6, IL-1 
and TNFo! expression in human monocytes [8,9]. IL-13 
is a novel T-helper cell lymphokine we have recently 
described [lO]. It has been shown that IL-13, like IL-4, 
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inhibits IL-6 and other inflammatory cytokines pro- 
duced by human monocytes [lo] as well as pyrogen- 
induced procoagulant activity in endothelial cells and 
monocytes [l l]. 
In the present work, we sought to determine whether 
IL-13 behaves like IL-4 in displaying a totally opposing 
effect, with respect o IL-6 secretion, when the target cells 
are of nanhematopoietic origin such as keratinocytes, 
We show that, similarly to IL-4, exposure to IL-13 stim- 
ulates keratinocytes to produce IL-6 This is the first 
report describing the ability of IL-13 to stimulate human 
keratinocytes. It therefore adds a new target cell for this 
novel pleiotropic cytokine. It also suggests that IL-13 
plays with IL-4 a critical role in activating epiderrnal cells 
during inflammation and certain autoimmune diseases. 
Keratinocyte. cell lines SVK14 (established by 3. ‘I’aylor-Papadiii- 
triou et al. [12]) and A431 (ATCC CRL 1555, [13]) were maintained in 
DMEM with 10% fetal calf serum (FCS). Normal human keratinocytes 
(NHK) were prepared’ from the skin of human female breast sections 
by Biopredic (Rennes, France) and grown in the same medium supple- 
mented with 10% FCS, 10 &ml epidermal growth factor and 5O&/ml 
bovine pituitary gland extract. The medium was changed every other- 
day. For IL-6 induction, cells were plated in triplicate at a density of 
5 x lo5 cells!ml in the presence of the stimuli. Supernatants were har- 
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vested at the indicated times, centrifuged at 400 x g and stored at -20” C 
until determination of cytokine content. 
2.2. Reagents and cytokines 
LPS (E. coli 055:B5) and polymyxin B were purchased from Sigma 
Chemicals (Saint-Quentin Fallavier, France). Human recombinant 
IL-4 (ARM 18005) was obtained from Amersham (Les Ulis, France) 
and human recombinant IL-13 was cloned, produced and purified as 
described [lo]. 
2.3. Measurement of cytokines 
IL-6, IL-la, IL-8 and TNFa were quantified using ELISA kits from 
Amersham (Biotrak RPN 2145, 2140, 2147, and 2148, respectively) 
according to the specifications of the manufacturer. The lower limit of 
detection was 3 pg/ml. The levels of biologically active IL-6 in culture 
supematants were also measured using the B9 bioassay [14] as de- 
scribed [lo]; values were determined by comparison with an IL-6 stand- 
ard. 
2.4. Northern blot analysis for measurement of IL-6 mRNA 
SVK14 keratinocytes were cultured 4 h in culture flasks in the pres- 
ence or absence of IO&ml LPS with fresh medium supplemented with 
10 ng/ml IL-4 or IL-13. As control, parallel flasks were similarly treated 
without the addition of cytokines. Total cellular RNA was extracted 
using guanidium isothiocyanate and purified by CsCl gradient ultracen- 
trifugation [ 151. Fifteen pg RNA aliquots were electrophoresed in 1% 
agarose gel using denaturating conditions and blotted onto nylon mem- 
branes. Hybridysation was carried out at 37°C in hybridisation buffer 
(Quick Hyb Stratagene) for 5 h with ‘*P-radiolabeled human IL-6 
cDNA probe. Final washes were at 43°C in 2 x SSC (1 x SSC = 0.3 M 
NaCl, 0.05 M NaCitrate, pH 7.0) and membranes were exposed for 
24 h to Kodak X-Qmat Iilm with an intensifier screen at -70°C. 
2.5. Statistical analysis 
Data were analysed by Student’s t-test. A cut-off value of P 5 0.05 
was used to indicate statistical significance. 
3. Results 
3.1. Effect of IL-13 on IL-6 production by keratinocytes 
The production of IL-6 by the SVK14 keratinocyte cell 
line was first evaluated using ELISA after a 24 h expo- 
sure with the indicated concentrations of IL-13 (Fig. 1). 
A comparison with IL-4 was done over an identical 
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Fig. 1. Effects of IL-13 and IL-4 on IL-6 production by SVK14 ker- 
atinocytes. Cells were incubated with the indicated concentrations of 
IL-4 or IL-13 for 24 h at 37°C. IL-6 levels were measured by ELISA. 
Values represent he mean f S.E.M. of triplicate cultures. The figure 
is representative of four separate xperiments. 
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Fig. 2. Effect of the associaton of IL-4 and IL-13 on IL-6 production 
by SVKl4 keratinocytes. Cells were treated 24 h with the indicated 
concentrations of IL-4 or IL-13 or both. IL-6 was evaluated by ELISA. 
Values represent he mean f S.E.M. of triplicate cultures. The figure 
is representative of three separate xperiments. 
range of concentrations within the same experiment. The 
results showed that both cytokines dose-dependently in- 
creased the production of IL-6 by keratinocytes. An ex- 
posure to 10 to 30 q/ml led to a 3-fold stimulation of 
IL-6 secretion (P 5 0.05). IL-4 was slightly more active 
displaying an EC&, of 0.8 @ml versus 3 n@nl for IL-13. 
As shown in Fig. 2, when IL-4 and IL-13 were used 
in combination at the optimal concentration of 20 ng/ml 
for 24 h, neither synergistic nor additive effects were 
found on the stimulation of IL-6. The association of IL-4 
and IL- 13 led to an increase of IL-6 production similar 
to what was observed with each cytokine taken alone 
@O&900 pg/ml in all cases in treated cells versus 200 
pg/ml in control cells )_ 
The kinetics of IL-13- and IL-4-induced IL-6 produc- 
tion were then compared using the B9 proliferation assay 
(Fig. 3). IL-4 and IL-1 3 at 10 ng/ml similarly induced a 
significant increase of IL-6 secretion (P 5 0.05) as soon 
as 6 h after exposure which continued until 24 h, at 
which time the stimulated SVK14 cells were producing 
approximately 3-fold more IL-6 than were the unstimu- 
lated cells. 
The property of IL-l 3 to stimulate IL-6 production by 
keratinocytes is a general phenomenon observed on an- 
other cell line (A431) and on normal human ker- 
atinocytes (NHK) as well. Table 1 shows that both IL- 13 
and IL-4 after a 24 h treatment at 10 rig/ml induced a 
significant 2.5- to 3-fold increase in IL-6 production 
whatever the type of keratinocytes. 
Considering the complex network of cytokines in- 
volved in inflammation, we sought to determine whether 
IL- 13 was also able to stimulate keratinocytes to produce 
other inflammatory cytokines such as IL-S, IL-l& and 
TNFu. In all cases, using immunoassays, the values ob- 
tained after exposure to either IL-13 or IL-4 (24 h at 10 
@ml) were below detection limit and we failed, under 
our conditions, to find any stimulating effect of IL- 13 or 
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IL-4 whereas control cells treated with 10 @ml of LPS 
produced significant amounts of these proinfla~atory 
cytokines, well above detection limit of the assay (data 
not shown). 
3.2. Absence of endotoxin contamination 
Endotoxin is known to be a potent inducer of IL-6 
secretion by keratinocytes [16,17]. Therefore, it was im- 
portant to know whether the phenomenon observed 
could be due to a contamination of the recombinant 
proteins with endotoxin. Pre-incubating IL-13 and IL-4 
with polymyxin B which binds LPS, did not affect their 
st~ulat~g effect whereas, in the same conditions, the 
level of IL-6 produced by LPS-stimulated cells was 
brought down to basal level (Fig. 4). Heating IL-13 and 
IL-4 to 70°C for 1 h before use completely abrogated 
their bioactivity while the stimulating effect of LPS re- 
mained unchanged (Fig. 4). 
3.3. AmpliJication by IL-13 and IL-4 of IL-6 mRNA and 
protein induced by LPS 
As shown in Fig. 5, using LPS (lO,~g/ml) as an inflam- 
matory stimulus, the level of IL-6 raised from 516 pglml 
in cells treated with LPS alone to 1290 and 1030 pglml 
in cells treated with a simultaneous combination of 
LPS + IL-4 or LPS + IL-13, respectively (P 5 0.05). A 
Northern blot analysis (Fig. 6) showed that similar to 
IL-4, the ability of IL-13 to induce an overexpression of 
IL-6 in LPS stimulated human keratinocytes was related 
to a higher accumulation of IL-6 transcripts. In both 
cases, a densitometric quantitation by an image analyser 
indicated an almost 2-fold increase of IL-6 mRNA com- 
pared to LPS control cells. In the absence of LPS, the 
stimulating effect of IL-13 and IL-4, demonstrated at the 
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Fig. 3. Kinetics of IL-13- and IL-Cinduced IL-6 production. SVK14 
keratinocytes were cultured with medium only or medium supple- 
mented with lOng/ml IL-4 or IL-13. At the times indicated, the levels 
of biologically functional IL-6 in culture supematants were measured 
using the B9 hybridoma proliferation assay. Values represent the 
mean ? S.E.M. of triplicate cultures. The figure is representative of 
three separate xperiments. 
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Fig. 4. Stimulation of IL-6 production is not due to endotoxin contam- 
ination. SVKl4 keratinocytes were incubated 24 h with medium only 
or medium supplemented with one of these agents: LPS , IL-4 , IL-1 3. 
The absence of endotoxin contamination was evaluated by pre-incu- 
bating these agents with polymyxin B (100 pg./ml) for 1 h or by heating 
them to 70°C for 1 h before addition. IL-6 production was measured 
as indicated in Fig. 1. The figure i representative of two separate 
experiments. 
level of IL-6 protein, was not detectable at the level of 
mRNA probably because of the low sensiti~ty of the 
Northern blot analysis. 
In the experiments of Figs. 5 and 6 we clearly showed 
that IL-4 and IL-13 were also able to act in concert with 
an already potent inducer leading to an overexpression 
of IL-6 at both transcriptional and translational evels. 
4. Discussion 
The results presented here show a great similarity be- 
tween IL-13 and IL-4 in stimulat~g IL-6 production by 
human keratinocytes although IL-4 seemed to be slightly 
more potent. IL-4 and IL-13 not only stimulated IL-6 
production per se but also amplified IL-6 expression 
induced by a primary inflammatory signal such as LPS. 
This was observed at the level of RNA and protein. This 
is the first report of such a biological effect of IL-13, a 
recently described lymphokine [lo], on this type of cells. 
Table 1 
Effects of IL-4 and IL-13 on the production of IL-6 by normal ker- 
atinocytes and keratinocyte cell lines. Normal human keratinoeytes 
(NHK) or keratinocyte cell lines (A431 and SVK14) were cultured with 
IL-4 or IL-13 for 24 h at 37’C. IL-6 content in cell-free supematants 
was measured by ELISA. Values represent he mean 2 S.E.M. of trip- 
licate cultures. 
IL-6 @g/ml) 
Treatment NHK A431 SVK14 
Control 65+ 5 16 t 2 98 ?z 10 
IL-4 10 &ml 180 zb 15 52 + 7 325 f 22 
IL-13 10 @ml 156 1: 12 45 f 5 276 + 18 
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This study further reinforces the homology found be- 
tween the biological activities of IL-4 and IL-13. We 
previously demonstrated that IL-4 and IL-13 displayed 
comparable abilities to inhibit inflammatory cytokine 
synthesis in LPS stimulated monocytes [lo]. More re- 
cently, it was shown that both IL-4 and IL-13 inhibit the 
procoagulant activity of monocytes and endothelial cells 
exposed to inflammatory mediators [l 11. This similarity 
of action could be explained, at least in part, by the fact 
that these two lymphokines share a common receptor 
component hat is important for signal transduction [181. 
In line with this finding, when IL-4 and IL-13 were used 
in combination on keratinocytes , neither synergistic nor 
additive effects were found on the upregulation of IL-6 
production, suggesting a common transduction pathway 
in this model . Indeed, cross-competition for receptor 
binding is seen between IL-4 and IL-13 on A43 1 ker- 
atinocytes (N. Vita, personnal communication). 
IL-6 which is an important mediator in normal and 
pathological immune reactions [19-211, like other cyto- 
kines, does not function in isolation. We therefore sought 
to evaluate whether IL-4 and IL-13 were able to stimu- 
late keratinocytes to produce other proinflammatory cy- 
tokines such as TNF&, IL-l, and IL-% Under our condi- 
tions, we failed to find any stimulating effect of IL-4 and 
IL-13 on these cytokines. A more sensitive approach 
such as the polymerase chain reaction is needed to totally 
rule out any influence of IL-4 and IL-13 on the expres- 
sion of these mediators by human keratinocytes. 
IL-6 expression can be downregulated or upregulated 
by various cytokines in a cell type and tissue specific 
manner. For exemple TNF& [22] and IL-4 [6] stimulate 
IL-6 gene expression in fibroblasts. IL-4 downregulates 
IL-6 production by human monocytes 9 but upregulates 
the same cytokine in B lymphocytes [23], endothelial cells 
[5] and keratinocytes [7]. IL-13 shows the same profile of 
action than IL-4: downregulation of IL-6 in monocytes 
[lo], upregulation on nonhematopoietically-derived cells 
of the skin such as keratinocytes (this study). 
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Fig. 5. Amplification of LPS-induced IL-6 production by IL-4 or IL-13. 
SVK14 keratinocytes were incubated for 24 h with IL-4 or IL-13 in the 
presence or absence of LPS . IL-6 levels were measured as described 
in Fig. 1. The figure is representative of three separate xperiments. 
35 
Fig. 6. Effects of IL-4 and IL-13 on IL-6 mRNA levels. SVK14 ker- 
atinocytes were incubated in the presence or absence of 10 pg/ml LPS 
with medium only or medium supplemented with 10 ng/ml IL-4 or 
IL-13. Total RNA was prepared and used in Northern blot analysis as 
described in section 2. The joint bands above IL-6 mRNA corre- 
sponded to cross hybridization of IL-6 probe with 1% rRNA which 
confirmed equal amounts of RNA in each lane. The figure is represen- 
tative of two separate xperiments. 
The role of IL-4 and IL-1 3 in stimulating IL-6 in 
epidermal cells may be directly relevant in vivo in au- 
toimmune skin diseases such as scleroderma [24] and 
psoriasis [25] where overproduction of IL-6 has been 
implicated and activated T-cell infiltrates with a helper- 
inducer phenotype have been observed [1,26,27]. Thus 
IL- 4 and IL-13 which both are products of helper T- 
cells, may be directly involved in the pathogenesis of 
these diseases by locally increasing the IL-6 production 
in affected sites. More generally, IL-4 and IL-13 are 
pleiotropic cytokines which seem to play a crucial role 
in the regulation of inflammatory processes at a local 
and systemic level. The biological significance of the ap- 
parent redundancy displayed by these two regulators 
remains to be elucidated. 
References 
[l] Kupper,T.S. (1990) J. Clin. Invest. 86, 1783-1789. 
[2] Kishimoto, T. (1989) Blood 74, l-10. 
[3] Krueger, J., Ray, A., Tamm, I. and Seghal, P.B. (1991) J. Cell. 
Biochem. 45, 327-334. 
[4] Turksen, K., Kupper, T., Degenstein, L., Williams, I. and Fuchs, 
E. (1992) Proc. Natl. Acad. Sci. USA 89, 5068-5072. 
[5] Howells, G., Pham, P., Taylor, D., Foxwell, B. and Feldmann, M. 
(1991) Eur. J. Immunol. 21, 97-101. 
[6] Feghali, CA., Bost, K.L., Boulware, D.W. and Levy, L.S.(1992) 
Clin. Immunol. Immunopathol. 63, 182-187. 
[7l Kupper, T.S., Min, K., Sehgal, F?, Mixutani, H., Birchall, N., Ray, 
A. and May, L. (1989) Ann. N.Y. Acad. Sci. 557, 45H65. 
[8] Essner, R., Rhoades, K., MC Bride, W.H., Morton, D.L. and 
Economou, J.S. (1989) J. Immtmol. 142, 3857-3861. 
[9] Lee, J.D., Swisher, S.G., Minehart, E.H., MC Bride, W.H. and 
Economou, J.S. (1990) J. Leukocyte Biol. 47, 475479. 
[lo] Minty, A., Chalon, P., Derocq, J.-M., Dumont, X., Guillemot, 
J.-C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, 
B., Minty, C., Casellas, P., Loison, G., Lupker, J., Shire, D., 
Ferrara, P. and Caput, D. (1993) Nature 362, 248-250. 
[l l] Herbert, J.-M., Savi, P., Laplace M.-C. Lalt, A., Dol, F., Dumas, 
A., Labit, C. and Minty, A. (1993) FEBS Lett. 328, 268-270. 
36 J.-M. Derocq et al. IFEBS Letters 343 (1994) 32-36 
[12] Taylor-Papadimetriou, J. Purkis, P., Lane, E.B., MC Kay, I. and 
Chang, S.E. (1982) Cell. Differ. 11, 169-180. 
[13] Giard, D.J., Aaronson, S.A., Torado, G.J., Amstein, P., Kersey, 
J.H. and Parks, W.P. (1973) J. Natl. Cancer Inst. 51, 1417-1423. 
[14] Aarden, L., Lansdorp, P. and Deroot, E. (1985) Lymphokines 10, 
175182. 
[15] Chirgwin, J.M., Przyhyla, A.E., Mac Donald, R.J. and Rutter 
W.J. (1979) Biochemistry 18, 5294-5299. 
[16] Kimbauer, R., Koch, A., Schwartz, T., Urbanski, A., Krutmann, 
J., Borth, W., Damm, D., Shipley, G., Ansel, J.C. and Luger, T. 
(1989) J. Immunol. 142, 1922-1928 
[17] Partridge, M., Chantry, D., Turner, M. and Feldmann M. (1991) 
J. Invest. Dermatol. 96, 771-776. 
[18] Zurawski, S.M., Vega Jr, F., Huyghe, B. and Zurawski, G. (1993) 
EMBO J. 12,2663-2670. 
[ 191 Sehgal, P.B., Grieninger, G. and Tosato, G. (1990) Ann. N.Y. 
Acad. Sci. 557, l-583. 
[20] Hirano, T., Akira, S., Taga, T. and Kishimoto, T. (1990) Immunol. 
Today 11,443449. 
[21] Sehgal, P.B. (1990) J. Invest. Dermatol. 94, 2S-6s. 
[22] Walther, Z., May, L.T. and Sehgal, P.B. (1988) J. Immunol. 140, 
974-977. 
[23] Smeland, E.B., Blomhoff, H.K., Funderud, S., Shalaby, M.R. and 
Espevik, T. (1989) J. Exp. Med. 170, 14631468. 
[24] Feghali, CA., Bost, K.L., Boulware, D.W. and Levy, L.S. (1992) 
J. Rheumatol. 19, 1207-1211. 
[25] Grossman, R.M., Kruger, J., Granelli-Pipemo, A., Murphy, D.P., 
May, L.T., Kupper, T.S., Sehgal, P.B. and Gottlieb, A. (1989) 
Proc. Natl. Acad. Sci. USA 86,63676371. 
[26] Geppert, T.G. (1990) Am. J. Med. Sci. 299, 193-209. 
[27] Ferrarini, M., Steen, U., Medsger Jr, T.A. and Whiteside T.L. 
(1990) Clm. Exp. Immunol. 79, 346352. 
